<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.81012</article-id><article-id pub-id-type="publisher-id">ACM-23909</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180100000_46532609.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胆固醇7α-羟化酶的研究进展
  The Progress in Study of Cholesterol 7 Alpha Hydroxylas
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>凛</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梁</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>上海岳阳中西医结合医院，上海</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>153229647@qq.com(闫凛)</email>;<email>twochao@163.com(梁超)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>02</month><year>2018</year></pub-date><volume>08</volume><issue>01</issue><fpage>64</fpage><lpage>68</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   胆固醇7α-羟化酶(cholesterol 7α-hydroxylase, CYP7A1)是催化胆固醇在肝脏分解为胆汁酸的限速酶，受多种因子调控，以维持胆固醇代谢平衡，多种中药及饮食成分对CYP7A1的基因表达有明显调节作用，影响血脂代谢，本文就CYP7A1基因的研究进展综述如下。 Cholesterol 7 alpha hydroxylase is the speed limiting enzyme that catalyzes the decomposition of cholesterol into the bile acid in the liver, regulated by a variety of factors, maintaining the balance of cholesterol metabolism, kinds of traditional Chinese medicine and food effect the gene expression of CYP7A1, influencing blood lipid metabolism. In this paper, the progress in study of CYP7A1 gene is summarized as follows. 
  
 
</p></abstract><kwd-group><kwd>胆固醇7α-羟化酶(CYP7A1)，胆固醇代谢，中药，调控，综述, Cholesterol 7 Alpha Hydroxylase</kwd><kwd> Cholesterol Metabolism</kwd><kwd> Traditional Chinese Medicine</kwd><kwd> Regulation</kwd><kwd> Overview</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>胆固醇7α-羟化酶的研究进展<sup> </sup></title><p>闫凛，梁超</p><p>上海岳阳中西医结合医院，上海</p><p>收稿日期：2018年2月7日；录用日期：2018年2月21日；发布日期：2018年2月28日</p><disp-formula id="hanspub.23909-formula10"><graphic xlink:href="//html.hanspub.org/file/12-1570472x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>胆固醇7α-羟化酶(cholesterol 7α-hydroxylase, CYP7A1)是催化胆固醇在肝脏分解为胆汁酸的限速酶，受多种因子调控，以维持胆固醇代谢平衡，多种中药及饮食成分对CYP7A1的基因表达有明显调节作用，影响血脂代谢，本文就CYP7A1基因的研究进展综述如下。</p><p>关键词 :胆固醇7α-羟化酶(CYP7A1)，胆固醇代谢，中药，调控，综述</p><disp-formula id="hanspub.23909-formula11"><graphic xlink:href="//html.hanspub.org/file/12-1570472x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/12-1570472x7_hanspub.png" /> <img src="//html.hanspub.org/file/12-1570472x8_hanspub.png" /></p></sec><sec id="s3"><title>1. CYP7A1基因特点</title><p>胆固醇7α-羟化酶又称为胆固醇7α-单氧酶或细胞色素P450 7A1酶，属肝脏特异性微粒体细胞色素P450酶系，该酶催化胆固醇在肝脏分解为胆汁酸，是该反应的限速酶。机体有两条胆汁酸生存途径，即经典途径和替代途径，CYP7A1和CYP27分别是这两条途径的限速酶，前者合成占70%以上，因此CYP7A1基因的表达对维持胆固醇和胆汁酸的平衡起重要作用。胆固醇7α-羟化酶(CYP7A1)位于人类染色体8q<sup>11</sup>-q<sup>12</sup>，全长约10kb，含6个外显子和5个内含子，编码503个氨基酸 [<xref ref-type="bibr" rid="hanspub.23909-ref1">1</xref>] 。<sup> </sup></p></sec><sec id="s4"><title>2. CYP7A1基因多态性与疾病及治疗的关系</title><p>在5’非翻译区侧翼区除有高度保守的调控元件TATAA和CCAAT外，还有一些能与肝脏特异转录因子结合的位点，其中的siteI位点就是LXRα-RXR复合物结合位点。在3’非翻译区中含9个AU富集因子(AREs)，这被认为是胆汁酸对CYP7A1基因表达进行负调控的靶位点。</p><p>赵燕等提取胆囊结石择期手术病人组血细胞DNA，对比正常人组发现CYP7A1基因多态性无显著性差异，仅胆石组和对照组中AA基因型患者LDL-C水平低于同组内AC、CC基因型患者，因此CYP7A1可能通过影响胆固醇水平继而影响胆固醇结石的发生 [<xref ref-type="bibr" rid="hanspub.23909-ref2">2</xref>] 。</p><p>王程强等研究人群中CYP7A1基因多态性，发现AA基因型在LDL-C，TC，Lp(a)水平上低于其他基因型，CC基因型在HDL-C水平上均高于其他基因型，且具有显著性差异，推测CYP7A1的基因型多态性与儿童的血脂水平存在密切的关系 [<xref ref-type="bibr" rid="hanspub.23909-ref3">3</xref>] 。</p><p>迟静等对比中老年人血脂异常组和正常人组血清总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和CYP7A1基因多态性，显示携带CYP7A1基因突变的个体，发生脂代谢紊乱的风险增高 [<xref ref-type="bibr" rid="hanspub.23909-ref4">4</xref>] 。</p><p>Lan X等发现一种新型长链非编码RNA Lnc-HC，与hnRNPA2B1结合，进一步与CYP7A1或者Abca1的信使RNA结合，从而降低CYP7A1或者Abca1的表达，而Lnc-HC基因敲除可有效的恢复体内胆固醇症 [<xref ref-type="bibr" rid="hanspub.23909-ref5">5</xref>] 。</p><p>崔云峰等研究家族性胆固醇结石患者、散发性胆固醇结石患者和非结石患者肝组织CYP7A1mRNA的表达，利用RT-PCR技术，发现家族遗传性组和散发性胆固醇结石组两组间mRNA的表达无明显差异，相对于非结石患者，胆囊结石患者肝组织CYP7A1mRNA水平降低，因而CYP7A1表达下降可能是胆囊胆固醇结石形成的重要原因之一，也是胆囊胆固醇结石发生的一个重要基因 [<xref ref-type="bibr" rid="hanspub.23909-ref6">6</xref>] 。</p></sec><sec id="s5"><title>3. 胆汁酸对CYP7A1表达的负反馈调控</title><p>胆汁酸负反馈抑制CYP7A1基因表达，因为肝受体同系物1(LXR-1)是CYP7A1的强激活剂，胆汁酸激活法呢醇X受体(FXR)，诱导小异二聚体伴侣(SHP)表达，SHP结合到LRH-1和LXRα，从而抑制CYP7A1的表达。另一方面，胆固醇则激活CYP7A1的表达，胆固醇激活LXRα，形成LXRα视黄醛衍生物受体(RXRα)异二聚体结合到CYP7A1基因I位点的DR-4模序，DR-4模序中含有合成胆汁酸反应的关键反应元件，从而激活CYP7A1基因的转录 [<xref ref-type="bibr" rid="hanspub.23909-ref7">7</xref>] 。</p></sec><sec id="s6"><title>4. 饮食因素对CYP7A1表达的调控</title><p>Kim B等利用含有乳酸菌高脂饮食喂养肥胖小鼠，相对于单纯高脂饮食喂养的肥胖小鼠，实验组小鼠肝脏、肠系膜、皮下脂肪的重量保持不变，甘油三脂和胆固醇总水平显著下降，P &lt; 0.05，是由介导上调FXRα的表达从而上调CYP7A1基因的表达所致，证实肠道益生菌可改善高脂血症和非酒精性脂肪肝 [<xref ref-type="bibr" rid="hanspub.23909-ref8">8</xref>] 。</p><p>Li X分别用等热量的高碳水化合物和高脂饮食喂养小鼠，发现两组小鼠体重接近但高碳水化合物饮食会增加总胆固醇浓度及降低CYP7A1的表达 [<xref ref-type="bibr" rid="hanspub.23909-ref9">9</xref>] 。</p><p>任明等对分组小鼠分别予以正常饮食、高脂饮食10周后处死，定量PCR法测定肝脏LRH-1及CYP7A1表达量，胆石组小鼠LRH-1mRNA及蛋白表达均高于对照组，CYP7A1mRNA及蛋白表达量较对照组升高。得出啮齿动物肝脏LRH-1和CYP7A1的表达异常与胆囊胆固醇结石形成有关，可能共同在小鼠胆结石形成中发挥作用 [<xref ref-type="bibr" rid="hanspub.23909-ref10">10</xref>] 。</p><p>McMilin M等利用消胆胺喂食小鼠或者CYP7A1基因敲除小鼠可以降低胆汁酸水平和延缓急性肝损伤造成的神经损害 [<xref ref-type="bibr" rid="hanspub.23909-ref11">11</xref>] 。</p><p>崔云峰等在造胆石症小鼠模型时显示高胆固醇膳食动物其CYP7A1mRNA表达降低，提示高胆固醇膳食诱发胆囊结石时CYP7A1基因转录水平的下调使胆汁胆固醇过饱和，促进了结石的形成 [<xref ref-type="bibr" rid="hanspub.23909-ref6">6</xref>] 。</p></sec><sec id="s7"><title>5. CYP7A1表达昼夜节律调控机制</title><p>Vlachova等证实CYP7A1基因的基因多态性在CYP7A1活性的昼夜变化有显着的影响，等位基因携带者对消胆胺和鹅去氧胆酸引起的酶活性反应无差别，在对照试验中203A等位基因携带者的酶反应表现出昼夜变化，而在203C等位基因携带者中无变化 [<xref ref-type="bibr" rid="hanspub.23909-ref12">12</xref>] 。Ferrell JMD等发现睡眠的中断会抑制具有昼夜节律性CYP7A1基因的表达 [<xref ref-type="bibr" rid="hanspub.23909-ref13">13</xref>] 。李文凯等发现长期予以临床剂量阿托伐他汀可增加CYP7A1的表达，同时可以提高调控时钟基因的核心基因Clock、Baml1的表达 [<xref ref-type="bibr" rid="hanspub.23909-ref14">14</xref>] 。</p></sec><sec id="s8"><title>6. 激素及细胞因子等对CYP7A1表达的调控及其调控通路</title><p>有研究者在制作孕鼠胆汁淤积模型发现高雌激素可诱导肝脏FXR的大量表达，可使CYP7A1表达增加，导致胆汁酸合成增加 [<xref ref-type="bibr" rid="hanspub.23909-ref15">15</xref>] 。Jiang Z等利用雷公藤对比雌鼠和雄鼠LXRα和LXRα靶点基因CYP7A1表达差异，表明大鼠的LXRα介导调节的CYP7A1基因表达存在性别差异 [<xref ref-type="bibr" rid="hanspub.23909-ref16">16</xref>] 。肝X受体α(LXRα)和维甲酸X受体α(RXRα)结合后形成LXRα-RXRα，LXRα-RXRα通过与CYP7A1基因启动子区的site I位点结合，以配体依赖方式激活转录。肝同系物受体I(LRH-I)以单体形式结合到CYP7A1基因上，是CYP7A1表达的基因调节因子，它作为一个活性因子允许LXR激活CYP7A1转录。</p><p>杨英昕等在研究胆宁片对大鼠脂肪肝及PPARα、CYP7A1表达的影响时观察CYP7A1mRNA表达与PPARαmRNA表达正相关，PPARα能促进CYP7A1的表达及胆汁酸的合成 [<xref ref-type="bibr" rid="hanspub.23909-ref16">16</xref>] 。另有研究显示PPARα基因敲除小鼠CYP7A1mRNA表达并不增加，表明CYP7A1的转录表达是依赖PPARα [<xref ref-type="bibr" rid="hanspub.23909-ref17">17</xref>] 。</p></sec><sec id="s9"><title>7. 药物及其组分对CYP7A1表达的调控</title><p>李文凯等在利用大鼠检测阿托伐他汀安全性时发现长期予以临床剂量阿托伐他汀可增加CYP7A1的表达 [<xref ref-type="bibr" rid="hanspub.23909-ref13">13</xref>] 。佛手提取物作用于人肝HepG2细胞，能上调CYP7A1、PPARα和HNF4α的蛋白表达量，沉默调控因子PPARα后，CYP7A1的蛋白表达量显著下降 [<xref ref-type="bibr" rid="hanspub.23909-ref18">18</xref>] 。Feng D等实验证明中成药血脂康通过提高CYP7A1的表达，加强胆汁酸的代谢，抑制肠道胆固醇的吸收来调控胆固醇平衡 [<xref ref-type="bibr" rid="hanspub.23909-ref19">19</xref>] 。</p><p>杨英昕等研究中成药胆宁片对高脂饮食大鼠脂肪肝的治疗及对CYP7A1mRNA表达的影响，与模型组比较，胆宁片能提高干细胞CYP7A1mRNA的表达，且优于阳性对照组熊去氧胆酸，其机制可能与其诱导CYP7A1表达，促进肝脏摄取、氧化脂肪酸与胆固醇有关 [<xref ref-type="bibr" rid="hanspub.23909-ref20">20</xref>] 。</p><p>黄名威等在研究大黄灵仙胶囊对普通豚鼠CYP7A1mRNA表达的影响，随机分为模型组、治疗组、正常对照组，以致石饲料喂养模型组和治疗组，常规饲料喂养正常对照组，造模开始后治疗组每日予大黄灵仙胶囊灌胃，模型组和正常对照组以等体积胜利盐水灌胃，结果表明，模型组豚鼠肝组织CYP7A1mRNA表达较正常对照组有明显下调，治疗者豚鼠肝组织CYP7A1mRNA的表达却是模型组的2.13倍。通过病理推测肝细胞的损伤可能直接导致CYP7A1基因表达下调。而大黄灵仙胶囊对组织保护的作用稳定了CYP7A1mRNA的表达，从而间接起到预防结石形成的作用 [<xref ref-type="bibr" rid="hanspub.23909-ref21">21</xref>] 。</p><p>潘祥宾等对采用球囊损伤家兔颈动脉予以高脂饮食，造模成功后分组予以养心颗粒、辛伐他丁、空白对照研究，用ELLSA法检测胆固醇7-α-羟化酶和MMP-9含量，养心颗粒组与辛伐他丁组与空白对照组比较，CYP7A1含量明显升高、MMP-9含量减少，且两治疗组相互比较差异无统计学意义，从而得出结论养心颗粒可升高易损斑块家兔模型血清CYP7A1含量，降低MMP-9表达 [<xref ref-type="bibr" rid="hanspub.23909-ref22">22</xref>] 。</p><p>张静喆等观察清胆胶囊对胆固醇结石小鼠的研究发现，可通过增强肝脏过氧化物酶体增殖物激活受体(PPAR)-γ、CYP7A1表达改善脂代谢 [<xref ref-type="bibr" rid="hanspub.23909-ref23">23</xref>] 。</p><p>苯扎贝特被广泛认为是降血脂药，近来其潜在的抗胆汁淤积作用被用来治疗原发性胆汁性肝硬化，研究表明其抗胆汁淤积的作用机制之一为降低CYP7A1的表达 [<xref ref-type="bibr" rid="hanspub.23909-ref24">24</xref>] 。</p><p>巩阳等对经内镜逆行胰胆管造影+十二指肠乳头切开取石术后胆总管结石患者分组，治疗组常规治疗加服加减益肝化石汤，服药前、服药后第七天和一个月采血，检测血CYP7A1mRNA表达，结果显示服中药组第七天、1个月CYP7A1mRNA的表达明显强于服药前，对照组治疗前后CYP7A1mRNA的表达无差异。从而表明益肝化石汤能通过上调CYP7A1基因的表达，使CYP7A1的蛋白表达增加，以减少结石形成 [<xref ref-type="bibr" rid="hanspub.23909-ref25">25</xref>] 。</p><p>综上所述，CYP7A1作为近10年来新发现的降脂作用靶点，可加快胆固醇转化为胆汁酸，有降血胆固醇功效。其基因表达受多个因子的调控，维持胆固醇的代谢平衡，具有较好的研究前景。目前的研究大多数对CYP7A1基因的表达水平，对CYP7A1的具体调节机制，还有待进一步研究，重要具有多成分，多靶点，多环节综合调节作用的特点，开展中药调控CYP7A1作用的特异信号途径及其靶点，有助于阐明中医药调脂作用机制，有助于合理有效选择降脂药物，为人类的健康带来巨大益处。</p></sec><sec id="s10"><title>文章引用</title><p>闫 凛,梁 超. 胆固醇7α-羟化酶的研究进展The Progress in Study of Cholesterol 7 Alpha Hydroxylas[J]. 临床医学进展, 2018, 08(01): 64-68. http://dx.doi.org/10.12677/ACM.2018.81012</p></sec><sec id="s11"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.23909-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">型万佳, 等. 胆固醇7α-羟化酶CYP7A1表达及调控相关研究进展[J]. 世界华人消化杂志, 2016, 20(16): 1439-1440</mixed-citation></ref><ref id="hanspub.23909-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">赵燕, 姚友贵. 胆固醇7α-羟化酶基因多态性与胆固醇结石病关系的研究[J]. 中国普外基础与临床杂志, 2010, 17(1):  60-61</mixed-citation></ref><ref id="hanspub.23909-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王程强, 等. 胆固醇7α-羟化酶基因多态性与小儿血脂的关系[J]. 海南医学院学报, 2008, 14(1).</mixed-citation></ref><ref id="hanspub.23909-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">迟静, 等. CYPA1基因多态性对脂代谢异常人群的影响[J]. 中国公共卫生, 2013, 29(4).</mixed-citation></ref><ref id="hanspub.23909-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lan, X., et al. (2016) A Novel Long Noncoding RNA Lnc-HC Binds hnRNPA2B1 to Regulate Expressions of Cyp7a1 and Abca1 in Hepatocytic Cholesterol Metabolism. Hepatology, 64, 58.</mixed-citation></ref><ref id="hanspub.23909-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">崔云峰, 崔乃强, 等. 家族性胆固醇结石患者肝组织CYP7A1mRNA的表达[J]. 中国中西医结合外科杂志, 2005, 11(3): 179-181.</mixed-citation></ref><ref id="hanspub.23909-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">范辉, 等. 以调节胆固醇7α-羟化酶为靶标的生物活性成分研究进展[J]. 中国新医药杂志, 2011, 20(8): 692-693.</mixed-citation></ref><ref id="hanspub.23909-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kim, B., et al. (2016) Protective Effects of Lactobacillus rhamnosus GG against Dyslipidemia in High-Fat Diet-Induced Obese Mice. Biochemical and Biophysical Research Communications, 473, 530-536.  
https://doi.org/10.1016/j.bbrc.2016.03.107</mixed-citation></ref><ref id="hanspub.23909-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., et al. (2015) Isocaloric Pair-Fed High-Carbohydrate Diet Induced Diet Induced more Hepatic Steatosis and Inflammation than High-Fat Diet Mediated by miR-34a/SIRT1 Axis in Mice. Scientific Reports, 5, 16774.  
https://doi.org/10.1038/srep16774</mixed-citation></ref><ref id="hanspub.23909-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">任明, 郭嵩, 等. 胆结石小鼠肝脏核受体基因LRH-1及其调控基因CYP7A1的表达[J]. 中国现代普外科进展, 2014, 17(10): 763.</mixed-citation></ref><ref id="hanspub.23909-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">McMilin, M., et al. (2016) Bile Acid Signaling Is Involved in the Neurological Decline in a Murine Model of a Acute Liver Failure. American Journal of Pathology, 186, 312-323. https://doi.org/10.1016/j.ajpath.2015.10.005</mixed-citation></ref><ref id="hanspub.23909-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Vlachova, et al. (2016) Diurnal Variation in Cholesterol 7α-Hydroxylase Activity Is Determined by the-203A ﹥ C Polymorphism of CYP7A1 Gene. Croatian Medical Journal, 57, 111-117. https://doi.org/10.3325/cmj.2016.57.111</mixed-citation></ref><ref id="hanspub.23909-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ferrell, J.M.D., et al. (2015) Short-Term Circadian Disruption Impairs Bile Acid and Lipid Homeostasis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 1, 664-677. https://doi.org/10.1016/j.jcmgh.2015.08.003</mixed-citation></ref><ref id="hanspub.23909-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李文凯, 徐永吉, 等. 阿托伐他汀诱导肝脏Cyp7a1和时钟基因的表达[J]. 中国药理学通报, 2016, 32(5): 739-740.</mixed-citation></ref><ref id="hanspub.23909-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">兰易, 刘建, 等. FXR, CYP7A1在妊娠期肝内胆汁淤积症孕鼠胆汁酸代谢中的作用[J]. 第三军医大学学报, 2008, 30(16): 1561-1563.</mixed-citation></ref><ref id="hanspub.23909-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, Z., et al. (2016) Sex-Related Differences of Lipid Metabolism Induced by Triptolide: The Possible Role of the LXRα/SREBP-1 Signaling Pathway. Frontiers in Pharmacology, 7, 87. https://doi.org/10.3389/fphar.2016.00087</mixed-citation></ref><ref id="hanspub.23909-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hunt, M.C., Yang, Y.Z., Eggertsen, G., et al. (2000) The Peroxisome Prolifera-tor-Actiated Receptor a (PPARα) Regulates Bile Acid Biosynthesis. The Journal of Biological Chemistry, 275, 28947-28953.  
https://doi.org/10.1074/jbc.M002782200</mixed-citation></ref><ref id="hanspub.23909-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">邓德城, 贝伟剑. 佛手提取物调控CYP7A1蛋白表达的研究[J]. 广东药学院学报, 2016, 32(2): 205-206.</mixed-citation></ref><ref id="hanspub.23909-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Feng, D., et al. (2015) Isoflavones and Phytosterols Contained in Xuezhikang Capsules Modulate Cholesterol Homeostasis in High-Fat Diet Mice. Acta Pharmacologica Sinica, 36, 1462-1472. https://doi.org/10.1038/aps.2015.98</mixed-citation></ref><ref id="hanspub.23909-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">杨英昕, 朱培庭, 等. 胆宁片对高脂模型大鼠脂肪肝及PPARα、CYP7A1表达的影响[J]. 中国新药与临床杂志, 2007, 26(10): 721-725.</mixed-citation></ref><ref id="hanspub.23909-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">黄名威, 唐乾利, 等. 大黄灵仙胶囊对胆结石豚鼠肝组织超微结构及CYP7A1mRNA表达的影响[J]. 中医杂志, 2010, 51(9): 837-839.</mixed-citation></ref><ref id="hanspub.23909-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">潘祥宾, 刘影哲, 等. 养心颗粒对易损斑块家兔模型胆固醇7-α-羟化酶和MMP-9含量的影响[J]. 中医药信息, 2012, 29(4): 60-61.</mixed-citation></ref><ref id="hanspub.23909-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">张静喆, 梁晓强, 等. 清胆胶囊对胆固醇结石小鼠肝脏中PPAR-γ, CYP7A1及NF-Kb表达的影响[J]. 中国中西医结合消化杂志, 2010, 18(4): 254-256.</mixed-citation></ref><ref id="hanspub.23909-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Honda, A., et al. (2013) Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid. Hepatology, 57, 1931-1941. https://doi.org/10.1002/hep.26018</mixed-citation></ref><ref id="hanspub.23909-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">巩阳, 朱虹, 等. 加减益肝化石汤阻止驱使术后胆石复发作用的观察及对胆汁成石基因的影响[J]. 中国中西医结合消化杂志, 2013, 21(2): 73-76.</mixed-citation></ref></ref-list></back></article>